Valuation: EyePoint, Inc.

Market Cap 1.17B 1.02B 942M 878M 1.66B 112B 1.69B 11.3B 4.39B 54.86B 4.4B 4.31B 189B P/E 2026 *
-3.97x
P/E 2027 * -5.11x
Enterprise Value 878M 767M 705M 657M 1.25B 83.58B 1.27B 8.47B 3.29B 41.08B 3.29B 3.22B 142B EV / Sales 2026 *
514x
EV / Sales 2027 * 19.6x
Free-Float
96.33%
Yield 2026 *
-
Yield 2027 * -
1 day+5.95%
1 week+1.97%
Current month-2.24%
1 month+11.57%
3 months+4.33%
6 months-20.02%
Current year-23.48%
1 week 13.01
Extreme 13.01
15.92
1 month 11.3
Extreme 11.295
15.92
Current year 11.3
Extreme 11.295
18.87
1 year 9.4
Extreme 9.4
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 67 09/07/2023
Director of Finance/CFO 61 13/11/2019
Chief Tech/Sci/R&D Officer 43 03/03/2024
Director TitleAgeSince
Director/Board Member 68 14/09/2016
Director/Board Member 67 09/07/2023
Chairman 77 09/09/2018
Date Insider Type Main position Quantity % Market Cap.
05-24Fiscal year

Chief Financial Officer

18,627 0.0222%
04-16Fiscal year

Chief Technology Officer

7,311 0.0088%
03-22Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+5.95%+1.97%+44.72%+60.69% 1.17B
+3.45%+7.65%+55.77%+158.84% 1,082B
-1.16%+7.42%+69.09%+58.92% 633B
-0.77%+7.37%+36.87%+93.77% 461B
-0.35%+1.85%+31.30%+24.86% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+0.40%+6.00%+17.72%+70.33% 163B
Average +1.57%+4.62%+33.00%+58.01% 370.09B
Weighted average by Cap. +1.04%+5.54%+42.20%+81.67%

Financials

2026 *2027 *
Net sales 1.71M 1.49M 1.37M 1.28M 2.42M 163M 2.46M 16.46M 6.4M 79.89M 6.41M 6.27M 275M 47.12M 41.19M 37.86M 35.29M 66.93M 4.49B 67.95M 454M 177M 2.21B 177M 173M 7.6B
Net income -311M -272M -250M -233M -442M -29.63B -449M -3B -1.17B -14.56B -1.17B -1.14B -50.18B -262M -229M -211M -197M -373M -24.99B -378M -2.53B -984M -12.29B -985M -964M -42.33B
Net Debt -294M -257M -236M -220M -418M -28.03B -424M -2.84B -1.1B -13.78B -1.1B -1.08B -47.47B -248M -217M -199M -186M -353M -23.64B -358M -2.39B -931M -11.62B -932M -912M -40.04B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
02/07/26 US$13.98 +5.95% 1,490,930
01/07/26 US$13.20 -7.73% 2,153,433
30/06/26 US$14.30 +1.35% 2,319,320
29/06/26 US$14.11 +3.29% 1,579,256
26/06/26 US$13.66 -0.36% 3,554,606
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.98USD
Average target price
40.00USD
Spread / Average Target
+186.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock